To evaluate the Safety and efficacy of a Unani formulations in the treatment of ZahÄ«r (Dysentery)

Clinical Validation of a Unani Pharmocopoeial Formulation â?? Sharbat-e-Belgiri in ZahÄ«r (Dysentery)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/12/006431

Enrollment

300

Registered

2015-12-08

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A060- Acute amebic dysentery

Interventions

Intervention1: Sharbat-e-Belgiri: 25 ml twice daily orally To be taken with water after meals for two weeks Control Intervention1: nil: nil

Eligibility

Inclusion criteria

Inclusion criteria: • Patients of either sex in the age group 18-65 years. • Patients of ZahÄ«r (Dysentery) having the following signs and symptoms: ï?§ 2-8 small-volume, semiformed or unformed stools/day ï?§ BarÄ?z DamwÄ« (Bloody Stools) and/or BarÄ?z MukhÄ?tÄ« (Mucoid Stools) ï?§ E. histolytica Cysts or Trophozoites in stools With or without any of the following: ï?§ Maghs (Tenesmus) ï?§ Wajaâ?? al-Batn Asfal (Lower Abdominal Pain) ï?§ ÄªlÄ?m al-Batn Asfal (Lower Abdominal Tenderness)

Exclusion criteria

Exclusion criteria: 1. Patients having diarrhoea with >8 stools/day 2. Moderate or severe dehydration 3. Fever (>=101 Â°F) 4. Patients having amoebic dysentery with any associated severe complications, e.g., fulminant colitis with perforation, paralytic ileus, toxic megacolon, ameboma, and liver abscess. 5. Clinical evidence of coexisting acute systemic illnesses 6. History or clinical evidence of chronic diseases requiring long-term treatment, e.g., DM, hypertension, tuberculosis, HIV infection, chronic liver disease, CKD, coeliac disease, IBD, or any other serious and/or unstable medical condition that, in the opinion of the investigator, could constitute a risk when taking study drug or could interfere with the interpretation of data. 7. Pregnant and lactating women 8. H/o Addiction (alcohol, drugs) 9. H/o Hypersensitivity to the study drug or any of its ingredients

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of Zimad e Bars of ZahÄ«r (Dysentery)Timepoint: 2 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessmentTimepoint: 2 weeks	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026